Oova’s Advanced Technology Yet Again Challenges What We Think We Know About Women’s Reproductive Health
NEW YORK, Aug. 3, 2023 /PRNewswire-PRWeb/ — Oova, Inc. is proud to announce the publication of its latest groundbreaking study in MDPI journal, Medicina, titled “Using Hormone Data and Age to Pinpoint Cycle Day within the Menstrual Cycle.” Conducted by esteemed scientists and co-authors, led by Dr. Amy Divaraniya, PhD founder of Oova, Inc., Dr. Mark B. Woodland, MD, Chair of Obstetrics and Gynecology at Tower Health, and Elinor Hills, content and brand lead at Oova, Inc, their discoveries bring a new understanding of the female reproductive cycle, particularly women with irregular periods, and confirms just how advanced and accurate remote hormone tracking has become.
Adding to Oova’s extensive collection of research and data on women’s hormone levels, the study challenges the standard norms used for comparison and disproves the assumption of a 28-day reproductive cycle. Shedding light on this inaccuracy and working towards a greater understanding of the female reproductive cycle. The study illustrates that the remote hormone monitoring platform can now analyze women’s cycles and pinpoint where an individual is in their cycle with minimal data points and the technology within Oova’s AI-powered app.
Oova, developed by Dr. Divaraniya, is a testing system that allows users to track their luteinizing hormone (LH) and pregnanediol-3-glucuronide (PdG) fluctuations throughout their cycles. The platform collects quantitative hormone measurements through urine to identify users’ unique fertile windows and predict ovulation. In this study, the Oova team evaluated hormone data from 4,123 cycles across 1,233 users, analyzing and tracking the LH and PdG via urine tests throughout menstrual cycles across different age groups.
Key Findings from the Study Include:
1. While 23.67% of women self-reported they had a 28-day cycle, only 5.23% actually did. Population-level data showed that women typically expected their cycle to be longer than it was.
2. Oova’s data challenged the assumption that a woman’s follicular and luteal phases are of equal lengths and that ovulation occurs exactly in the middle. Instead, the follicular phase was generally longer than the luteal phase. Furthermore, the data revealed that as women age, the length of the follicular phase decreases, while the luteal phase increases.
3. Using Oova’s hormone data to train their algorithm, Oova can now determine a woman’s cycle day based on her age and hormone levels with 95% confidence. This is groundbreaking, as it allows for a thorough understanding of a woman’s cycle, even if it’s irregular.
“Our mission at Oova is to empower women with an accurate understanding of their reproductive health, giving them control on their journey to pregnancy. Further, our mission is to challenge the status quo and debunk widely accepted inaccuracies to set new standards in women’s healthcare. This study is proof of our capabilities at Oova, and we can now say with confidence that at-home hormone monitoring offers more precise cycle tracking than textbook estimations, benefiting fertility planning, clinical management, and general health monitoring,” says Oova founder and study leader, Dr. Amy Divaraniya.
Dr. Divaraniya developed the OOVA technology after her own 18-month struggle to get pregnant. Over-the-counter hormone tests were not conducive to tracking her irregular menstrual and ovulation cycle. She has created advanced technology, that provides a hormone monitoring solution for women facing cycle irregularities, a symptom that studies have shown affects more than 87% of the female population [reference link . Oova’s data has been integral in discovering hormone patterns of Oova users in advanced maternal age. It has led to identifying hormone patterns that indicate patients’ presentation of signs of reproductive disorders such as PCOS. This latest study represents a groundbreaking advancement, as it reveals the possibility of precisely pinpointing where a person is in their cycle using only one measure of LH and PdG, a capability previously unattainable. These and future Oova findings have the potential to fill significant gaps within reproductive healthcare and beyond.
In addition to Oova’s consumer and clinician business, the company holds an ongoing study and research department. They are actively looking for partners to support their independent research. Past research collaborators include Massachusetts General Hospital, New Hope Fertility Center, and IRMS at St. Barnabas Hospital. If you’re interested in collaborating on additional research projects, please reach out to the Oova team at [email protected].
For all media inquires, please contact Sara Spiegel at [email protected]
For general inquiries, please contact [email protected]
About Oova, Inc.:
Oova is the fertility translator that fully illuminates a woman’s fertility, giving her and her care team the clearest steps to conception. Founded by doctors and backed by Mount Sinai Hospital, Oova has created a consumer-first, data-driven experience valuable to patients and healthcare providers. Oova’s at-home urine test measures luteinizing hormone and progesterone to immediately inform a woman of her most fertile days and confirm ovulation. By delivering advanced personalized analytics and real-time action plans with every hormone reading, Oova is transforming the fertility care experience. Oova has partnered with the leading fertility and women’s health practices in the United States. To learn more, visit Oova’s website.
Media Contact
Sara Spiegel, Oova, 937 478 9235, [email protected]
SOURCE Oova
